Specialty Pharma Journal Specialty, Precision & Technology
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (NASDAQ: VCYT) announced that new data highlighting the ability of the Percepta Bronchial Genomic Classifier to reduce unnecessary invasive procedures in lung cancer diagnosis will be shared in an oral presentation at CHEST 2018, the annual meeting of the American College of Chest Physicians®. In …
Tag Archives: IPF
September, 2018
-
19 September
Clinical Trial Data for Nintedanib in Patients with Advanced Idiopathic Pulmonary Fibrosis Published
Ingelheim, Germany, 16 September 2018 – Results from the INSTAGE® trial have been presented at the 2018 European Respiratory Society (ERS) conference in Paris and published in the New England Journal of Medicine.1 The trial reports clinical data on a subset of patients with IPF and severe impairment in gas exchange, for whom only …
August, 2018
-
6 August
FDA Grants Orphan Drug Designation to Pliant’s Investigational Idiopathic Pulmonary Fibrosis Therapy
SOUTH SAN FRANCISCO, Calif., Aug. 6, 2018 /PRNewswire/ — Pliant Therapeutics, Inc., a biotechnology company focused on discovering, developing and commercializing treatments for fibrotic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the company’s anti-fibrotic lead compound, PLN-74809, for the treatment …
November, 2017
-
28 November
Data Confirms Analytical Validity of Veracyte’s Envisia Genomic Classifier for Use in IPF Diagnosis
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (NASDAQ: VCYT) announced that data confirming the analytical validity of the company’s Envisia™ Genomic Classifier have been published online in the journal BMC Pulmonary Medicine. The findings add to the growing body of evidence, including previously reported clinical validity and clinical utility data, supporting the use …
October, 2017
-
23 October
Global Blood Therapeutics Discontinues Development of Idiopathic Pulmonary Fibrosis Program
SOUTH SAN FRANCISCO, Calif., Oct. 23, 2017 (GLOBE NEWSWIRE) — Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced the discontinuation of its GBT440 program for the treatment of idiopathic pulmonary fibrosis (IPF). This decision is based on results from three proof-of-concept studies including a Phase 1 study in healthy volunteers …
August, 2017
-
9 August
FibroGen’s Pamrevlumab Succeeds in Mid-Stage Idiopathic Pulmonary Fibrosis Study
SAN FRANCISCO, Aug. 07, 2017 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, announced today positive topline results from the company’s Phase 2 randomized, double-blind, placebo-controlled study and two combination safety sub-studies of pamrevlumab in patients with idiopathic pulmonary fibrosis (IPF). Pamrevlumab is a proprietary, first-in-class, anti-connective tissue growth factor (CTGF) antibody being …
May, 2017
-
22 May
Two Biomarkers Appear to Predict Course of Idiopathic Pulmonary Fibrosis
ATS 2017, WASHINGTON, DC — Two T cell biomarkers appear to predict the survival trajectory of patients with idiopathic pulmonary fibrosis (IPF), a lung disease that has a varied, but ultimately devastating, impact on patients, according to new research presented at the ATS 2017 International Conference. T-cells marshal the body’s …
June, 2016
-
10 June
Merck to Acquire Afferent Pharmaceuticals in $1.25 Billion Deal
KENILWORTH, N.J. & SAN MATEO, Calif., June 9, 2016 – Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Afferent Pharmaceuticals announced today that the two companies have signed a definitive agreement under which Merck will acquire this privately held pharmaceutical company. Afferent Pharmaceuticals is a leader …
March, 2015
-
17 March
Galapagos and Janssen End Inflammation Alliance
Galapagos NV and Janssen Pharmaceutica NV of Johnson & Johnson have ended their eight-year alliance to develop anti-inflammatory drugs. The companies originally entered into a worldwide multi-target alliance in October 2007, to discover and develop novel small-molecule therapeutics for the treatment of rheumatoid arthritis (RA), a deal which provided Galapagos …